This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation to viral clearance and its safety.
Drug: Nivolumab
Single dose at 0.3mg/kg
Other Name: Opdivo
Inclusion Criteria:
- Diagnosis of COVID-19 by RT-PCR for SARS-CoV-2
- Clinically stable with disease severity defined as mild or moderate (mild disease is
defined as symptoms with or without lung infiltrates on chest X-Ray or CT imaging;
moderate disease is defined as lung infiltrates with evidence of type 1 respiratory
failure)
- Asymptomatic patients may be enrolled if patients have obvious radiographic changes on
chest or CT radiography deemed to be related to COVID-19
Exclusion Criteria:
- Active cancer, rheumatological and autoimmune conditions
- Transplant recipients, or patients on active immunosuppressants
- Chronic organ impairment, or documented or suspected concomitant infections (including
chronic viral hepatitis B and hepatitis C) other than SARS-CoV-2
- Lactating mothers and women who are pregnant or intending to become pregnant
- Acute respiratory distress syndrome, evidence of myocardial injury, disseminated
intravascular coagulopathy, organ failure, hemophagocytosis, shock, respiratory
distress, or need for mechanical ventilation, AICU admission, or high flow oxygen
therapy
Gerry Gin Wai Kwok, MBBS
+852-22553111
gggjerry@gmail.com
Gerry Gin Wai Kwok, MBBS, Principal Investigator
Queen Mary Hospital, Hong Kong